Satoru Mitsuboshi

Satoru Mitsuboshi

Auto-generated profile, based on publicly available information

Satoru Mitsuboshi

Department of Pharmacy Kaetsu Hospital Niigata Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2022 in Journal of Pharmacy Technology
Verified
Journal Article
Closed access
KKKazumasa Kotake
Kazumasa Kotake
SMSatoru Mitsuboshi
Satoru Mitsuboshi
YOYuki Omori
Yuki Omori
YKYukio Kawakami
Yukio Kawakami
YKYasuhiro Kawakami
Yasuhiro Kawakami
Background: Romosozumab is associated with an increased risk of cardiac or cerebrovascular events. Identifying the risk factors for these events could contribute to the safe use of romosozumab. Objective: This study aimed to investigate risk factors for cardiac or cerebrovascular events in romosozumab users. Methods: First, disproportionality analysis was performed to compare the frequency of cardiac or cerebrovascular events, using data from the Japanese Adverse Drug Event Report database. Next, multivariate logistic analysis was performed to investigate risk factors for cardiac or cerebrovascular events in romosozumab users. Results: In total, 859 romosozumab users were identified. A disproportionality of both cardiac and cerebrovascular events was observed in only romosozumab users. Multivariate logistic analysis revealed that the risk of cardiac events in romosozumab users was significantly increased in patients with cardiac disease (odds ratio [OR]: 5.9, 95% confidence interval [CI] 3.5-9.9; P < 0.01) and hypertension (OR: 1.6, 95% CI 1.0-2.7; P = 0.047). In addition, the risk of cerebrovascular events in romosozumab users was significantly increased in the presence of cerebrovascular disease (OR: 2.7, 95% CI 1.2-6.2; P = 0.02) and hypertension (OR: 2.6, 95% CI 1.7-3.9; P < 0.01). Conclusion: Our findings suggest that hypertension may increase the risk of cardiac or cerebrovascular events in romosozumab users. Although additional studies are needed to assess other associated factors, these findings may contribute to the appropriate use of romosozumab and limit adverse events.

20 March 2023 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
TTToshiki Tezuka
Toshiki Tezuka
SOShinichi Okuzumi
Shinichi Okuzumi
CNChiho Nakashima
Chiho Nakashima
TIToshihiro Ide
Toshihiro Ide
SIShungo Imai 
Shungo Imai 
SSShigeaki Suzuki
Shigeaki Suzuki

17 June 2024 in Journal of Infection
Verified
Journal Article
Open access
SMSatoru Mitsuboshi
Satoru Mitsuboshi
SIShungo Imai 
Shungo Imai 
HKHayato Kizaki
Hayato Kizaki
SHSatoko Hori
Satoko Hori
To determine whether concomitant use of ceftriaxone and oral or intravenous lansoprazole increases the risk of ventricular arrhythmia and cardiac arrest in the real-world setting in Japan. The data analyzed were obtained from the JMDC hospital-based administrative claims database for the period April 2014 to August 2022. Patients who received a proton pump inhibitor (PPI) while receiving ceftriaxone or sulbactam/ampicillin were identified. The frequency of ventricular arrhythmia and cardiac arrest was analyzed according to whether oral or intravenous PPI was concomitant with ceftriaxone or sulbactam/ampicillin. Estimates of the incidence of ventricular arrhythmia and cardiac arrest were then compared among the groups, using the Fine-Gray competing risk regression model. The results showed that the risk of ventricular arrhythmia and cardiac arrest was significantly higher with concomitant ceftriaxone and oral lansoprazole (hazard ratio 2.92, 95% confidence interval 1.99-4.29, P < 0.01) or intravenous lansoprazole (hazard ratio 4.57, 95% confidence interval 1.24-16.80, P = 0.02) than with concomitant sulbactam/ampicillin and oral or intravenous lansoprazole. Oral and intravenous lansoprazole may increase the risk of ventricular arrhythmia and cardiac arrest in patients who are receiving ceftriaxone.

21 December 2022 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
TNTakahiro Niimura
Takahiro Niimura
YZYoshito Zamami
Yoshito Zamami
KMKoji Miyata
Koji Miyata
TMTakahisa Mikami
Takahisa Mikami
MAMizuho Asada
Mizuho Asada
KIKeisuke Ishizawa
Keisuke Ishizawa

25 November 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
SIShungo Imai 
Shungo Imai 
SMSatoru Mitsuboshi
Satoru Mitsuboshi
SHSatoko Hori
Satoko Hori
SSShigeaki Suzuki
Shigeaki Suzuki

11 November 2021 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MSMitsuboshi Satoru
Mitsuboshi Satoru
RKRyohei Kaseda
Ryohei Kaseda
INIchiei Narita
Ichiei Narita